Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

AIMS: A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with non-valvular atrial fibrillation in Spain. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar Cervantes, Carlos, Martí-Almor, Julio, Cabeza, Alejandro Isidoro Pérez, Bowrin, Kevin, Llorac Moix, Aleix, Genís Gironès, Mar, Gasche, David, Millier, Aurélie, Tardu, Jean, Toumi, Mondher, Briere, Jean-Baptiste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020681/
https://www.ncbi.nlm.nih.gov/pubmed/35443000
http://dx.doi.org/10.1371/journal.pone.0266658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020681/
https://www.ncbi.nlm.nih.gov/pubmed/35443000
http://dx.doi.org/10.1371/journal.pone.0266658

Ejemplares similares